ArticleRadiology case reports2026
Dramatically changing intracranial arteriopathy due to antiphospholipid syndrome: A case report.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is an autoimmune thrombophilia that rarely presents with progressive intracranial large-artery stenosis or occlusion, making early recognition difficult when vascular lesions mimic atherosclerotic disease. A 74-year-old female receiving edoxaban for atrial fibrillation presented with progressive left hemiparesis due to severe right internal carotid artery (ICA) stenosis. Angioplasty improved cerebral blood flow, but recurrent ischemic stroke occurred 3 months later due to restenosis, which was treated with repeat angioplasty and Wingspan stenting. Over the next year, she developed progressive right middle cerebral artery (MCA) stenosis that eventually led to occlusion, requiring superficial temporal artery-MCA bypass. After perioperative interruption of edoxaban, she developed in-stent thrombosis and bypass graft thrombosis. Laboratory testing revealed triple-positive antiphospholipid antibodies, confirming primary APS. Systemic heparinization followed by apixaban resulted in complete resolution of in-stent thrombosis, improved bypass flow, and partial MCA recanalization. This case illustrates that APS can present as a dramatically changing and potentially reversible intracranial arteriopathy, emphasizing the need to suspect APS in patients with recurrent or unexplained intracranial thrombosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.